Logo image of BOLD

BOUNDLESS BIO INC (BOLD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BOLD - US10170A1007 - Common Stock

1.18 USD
+0.04 (+3.51%)
Last: 12/9/2025, 8:00:02 PM
1.16 USD
-0.02 (-1.69%)
Pre-Market: 12/10/2025, 4:19:23 AM
Fundamental Rating

3

BOLD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BOLD as it has an excellent financial health rating, but there are worries on the profitability. BOLD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BOLD had negative earnings in the past year.
BOLD had a negative operating cash flow in the past year.
BOLD Yearly Net Income VS EBIT VS OCF VS FCFBOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

BOLD has a Return On Assets of -36.60%. This is in the better half of the industry: BOLD outperforms 61.02% of its industry peers.
The Return On Equity of BOLD (-56.06%) is better than 63.28% of its industry peers.
Industry RankSector Rank
ROA -36.6%
ROE -56.06%
ROIC N/A
ROA(3y)-43.16%
ROA(5y)N/A
ROE(3y)-51.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BOLD Yearly ROA, ROE, ROICBOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

BOLD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BOLD Yearly Profit, Operating, Gross MarginsBOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for BOLD has been increased compared to 1 year ago.
BOLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BOLD Yearly Shares OutstandingBOLD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
BOLD Yearly Total Debt VS Total AssetsBOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

BOLD has an Altman-Z score of -2.33. This is a bad value and indicates that BOLD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.33, BOLD is in line with its industry, outperforming 47.08% of the companies in the same industry.
BOLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.33
ROIC/WACCN/A
WACCN/A
BOLD Yearly LT Debt VS Equity VS FCFBOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 10.14 indicates that BOLD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 10.14, BOLD belongs to the top of the industry, outperforming 80.79% of the companies in the same industry.
BOLD has a Quick Ratio of 10.14. This indicates that BOLD is financially healthy and has no problem in meeting its short term obligations.
BOLD has a Quick ratio of 10.14. This is amongst the best in the industry. BOLD outperforms 80.79% of its industry peers.
Industry RankSector Rank
Current Ratio 10.14
Quick Ratio 10.14
BOLD Yearly Current Assets VS Current LiabilitesBOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BOLD have decreased strongly by -484.97% in the last year.
EPS 1Y (TTM)-484.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BOLD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.46% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y82.58%
EPS Next 2Y36.1%
EPS Next 3Y24.46%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BOLD Yearly Revenue VS EstimatesBOLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
BOLD Yearly EPS VS EstimatesBOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BOLD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BOLD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BOLD Price Earnings VS Forward Price EarningsBOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BOLD Per share dataBOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

BOLD's earnings are expected to grow with 24.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.1%
EPS Next 3Y24.46%

More info and screens

0

5. Dividend

5.1 Amount

BOLD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOUNDLESS BIO INC

NASDAQ:BOLD (12/9/2025, 8:00:02 PM)

Premarket: 1.16 -0.02 (-1.69%)

1.18

+0.04 (+3.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-23 2026-03-23
Inst Owners55.21%
Inst Owner Change-7.25%
Ins Owners3.03%
Ins Owner Change0%
Market Cap26.42M
Revenue(TTM)N/A
Net Income(TTM)-61.76M
Analysts45.71
Price Target3.06 (159.32%)
Short Float %0.31%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.97%
Min EPS beat(2)-5.58%
Max EPS beat(2)-4.35%
EPS beat(4)2
Avg EPS beat(4)0.05%
Min EPS beat(4)-5.58%
Max EPS beat(4)5.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.29%
PT rev (3m)-14.29%
EPS NQ rev (1m)25.2%
EPS NQ rev (3m)20.35%
EPS NY rev (1m)-0.95%
EPS NY rev (3m)-0.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.24
EV/EBITDA N/A
EPS(TTM)-2.77
EYN/A
EPS(NY)-2.15
Fwd EYN/A
FCF(TTM)-2.35
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS0
BVpS4.92
TBVpS4.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.6%
ROE -56.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.16%
ROA(5y)N/A
ROE(3y)-51.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.42%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.14
Quick Ratio 10.14
Altman-Z -2.33
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)137.61%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-484.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.22%
EPS Next Y82.58%
EPS Next 2Y36.1%
EPS Next 3Y24.46%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.81%
EBIT Next 3Y1.53%
EBIT Next 5YN/A
FCF growth 1Y-33.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.85%
OCF growth 3YN/A
OCF growth 5YN/A

BOUNDLESS BIO INC / BOLD FAQ

What is the fundamental rating for BOLD stock?

ChartMill assigns a fundamental rating of 3 / 10 to BOLD.


What is the valuation status for BOLD stock?

ChartMill assigns a valuation rating of 1 / 10 to BOUNDLESS BIO INC (BOLD). This can be considered as Overvalued.


What is the profitability of BOLD stock?

BOUNDLESS BIO INC (BOLD) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BOLD stock?

The Earnings per Share (EPS) of BOUNDLESS BIO INC (BOLD) is expected to grow by 82.58% in the next year.